Reactivación del virus de la hepatitis B en pacientes tratados con rituximab: incidencia y factores de riesgo
- 1 January 2015
- journal article
- Published by Elsevier in Gastroenterología y Hepatología
- Vol. 38 (1) , 1-6
Abstract
No abstract availableKeywords
This publication has 39 references indexed in Scilit:
- Fulminant hepatitis B following rituximab therapy in a patient with Evans syndrome and large B‐cell lymphomaAmerican Journal of Hematology, 2006
- Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapyHepatology, 2006
- Anti-HBs-Positive Liver Failure Due to Hepatitis B Virus Reactivation Induced by RituximabInternal Medicine, 2006
- Fulminant B hepatitis in a surface antigen-negative patient with B-cell chronic lymphocytic leukaemia after rituximab therapyLeukemia, 2005
- Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: Potential implications for future prophylaxis recommendationsLeukemia & Lymphoma, 2005
- HBV reactivation with fatal fulminating hepatitis during rituximab treatment in a subject negative for HBsAg and positive for HBsAb and HBcAbJournal of Infection and Chemotherapy, 2005
- Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapyBlood, 2003
- Acute Hepatitis B in a Patient with Antibodies to Hepatitis B Surface Antigen Who Was Receiving RituximabNew England Journal of Medicine, 2001
- Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: A prospective study of 626 patients with identification of risk factorsJournal of Medical Virology, 2000
- Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP ChemotherapyJournal of Clinical Oncology, 1999